Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-Assisted Group Therapy for PTSD in Veterans
NCT05173831Phase 2Withdrawn
- Sponsor
- Lykos Therapeutics
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Lykos Therapeutics. Primary endpoint: Change in Clinician Administered PTSD Scale for DSM-5 Total Severity Score at 3 months. Planned start Sep 2023; status: withdrawn.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05173831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05173831.